Literature DB >> 24911956

Bone Marrow Stromal Cells Combined With a Honeycomb Collagen Sponge Facilitate Neurite Elongation In Vitro and Neural Restoration in the Hemisected Rat Spinal Cord.

Madoka Onuma-Ukegawa1, Kush Bhatt, Takashi Hirai, Hidetoshi Kaburagi, Shinichi Sotome, Yoshiaki Wakabayashi, Shizuko Ichinose, Kenichi Shinomiya, Atsushi Okawa, Mitsuhiro Enomoto.   

Abstract

In the last decade, researchers and clinicians have reported that transplantation of bone marrow stromal cells (BMSCs) promotes functional recovery after brain or spinal cord injury (SCI). However, an appropriate scaffold designed for the injured spinal cord is needed to enhance the survival of transplanted BMSCs and to promote nerve regeneration. We previously tested a honeycomb collagen sponge (HC), which when applied to the transected spinal cord allowed bridging of the gap with nerve fibers. In this study, we examined whether the HC implant combined with rat BMSCs increases nerve regeneration in vitro and enhances functional recovery in vivo. We first evaluated the neurite outgrowth of rat dorsal root ganglion (DRG) explants cultured on HC with or without BMSCs in vitro. Regeneration of neurites from the DRGs was increased by BMSCs combined with HC scaffolds. In the in vivo study, 3-mm-long HC scaffolds with or without BMSCs were implanted into the hemisected rat thoracic spinal cord. Four weeks after the procedure, rats implanted with HC scaffolds containing BMSCs displayed better motor and sensory recovery than those implanted with HC scaffolds only. Histologically, more CGRP-positive sensory fibers at the implanted site and 5-HT-positive serotonergic fibers contralateral to the implanted site were observed in spinal cords receiving BMSCs. Furthermore, more rubrospinal neurons projected distally to the HC implant containing BMSCs. Our study indicates that the application of BMSCs in a HC scaffold in the injured spinal cord directly promoted sensory nerve and rubrospinal tract regeneration, thus resulting in functional recovery.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24911956     DOI: 10.3727/096368914X682134

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  7 in total

Review 1.  Regenerative Therapies for Spinal Cord Injury.

Authors:  Nureddin Ashammakhi; Han-Jun Kim; Arshia Ehsanipour; Rebecca D Bierman; Outi Kaarela; Chengbin Xue; Ali Khademhosseini; Stephanie K Seidlits
Journal:  Tissue Eng Part B Rev       Date:  2019-10-23       Impact factor: 6.389

2.  The future of bone marrow stromal cell transplantation for the treatment of spinal cord injury.

Authors:  Mitsuhiro Enomoto
Journal:  Neural Regen Res       Date:  2015-03       Impact factor: 5.135

3.  Recent advances in biomaterials for 3D scaffolds: A review.

Authors:  Maria P Nikolova; Murthy S Chavali
Journal:  Bioact Mater       Date:  2019-10-25

Review 4.  A Brief Overview of Global Trends in MSC-Based Cell Therapy.

Authors:  Dragomirka Jovic; Yingjia Yu; Dan Wang; Kuixing Wang; Hanbo Li; Fengping Xu; Chenglong Liu; Junnian Liu; Yonglun Luo
Journal:  Stem Cell Rev Rep       Date:  2022-03-28       Impact factor: 6.692

5.  Biocompatibility of reduced graphene oxide nanoscaffolds following acute spinal cord injury in rats.

Authors:  Ali H Palejwala; Jared S Fridley; Javier A Mata; Errol L G Samuel; Thomas G Luerssen; Laszlo Perlaky; Thomas A Kent; James M Tour; Andrew Jea
Journal:  Surg Neurol Int       Date:  2016-08-23

Review 6.  Biomaterial-Supported Cell Transplantation Treatments for Spinal Cord Injury: Challenges and Perspectives.

Authors:  Shengwen Liu; Thomas Schackel; Norbert Weidner; Radhika Puttagunta
Journal:  Front Cell Neurosci       Date:  2018-01-11       Impact factor: 5.505

7.  Tubular scaffold with microchannels and an H-shaped lumen loaded with bone marrow stromal cells promotes neuroregeneration and inhibits apoptosis after spinal cord injury.

Authors:  Xue Chen; Jian Wu; Rongcheng Sun; Yahong Zhao; Yi Li; Jingying Pan; Ying Chen; Xiaodong Wang
Journal:  J Tissue Eng Regen Med       Date:  2020-01-29       Impact factor: 3.963

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.